Aptamer Sciences Inc

Aptamer Sciences Inc has a market capitalization of KRW 47.62 billion and a price-to-book ratio of 3.67, indicating a premium valuation relative to its book value. The company's liquidity position is characterized by a current ratio of 1.49, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's operating cash flow is negative at KRW -2.2 billion, and its free cash flow is also negative at KRW -2.27 billion, indicating a lack of cash generation from operations.

The company's profitability metrics are weak, with a return on equity of -18.5% and a return on assets of -7.86%, both significantly below industry norms. The gross profit is negative at KRW -4.79 billion, and the operating income is negative at KRW -22.13 billion, reflecting substantial operational losses. These figures suggest the company is not currently generating sustainable profits and is likely in a high-growth or early-stage development phase.

Aptamer Sciences Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification increases the company's exposure to market-specific risks and could limit its growth potential if the primary market experiences downturns.

The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The current financial performance, characterized by negative operating and net income, suggests the company is not currently in a growth phase. The absence of detailed outlook data makes it difficult to assess future revenue trends or the company's ability to achieve profitability.

The company's risk profile is marked by a medium liquidity risk and a low dilution risk. The key financial flag is the negative net cash position after subtracting total debt, which indicates potential liquidity constraints. The debt-to-equity ratio of 0.67 suggests a moderate level of leverage, but the company's negative cash flows could pose challenges in maintaining this leverage profile without additional financing.

Recent events and filings do not provide specific details on the company's strategic initiatives or financial developments. The absence of recent transcripts or detailed filings limits the ability to assess the company's management strategy or operational progress. Investors should monitor the company's upcoming filings for more detailed insights into its financial health and strategic direction.

Revenue surged 223.7% year-over-year to 3.5 billion KRW, demonstrating significant top-line growth momentum.

The company achieved an 89.9% revenue CAGR over four years, indicating strong historical expansion trends.

Cash conversion ratio of 0.92 exceeds the cohort median of 0.87, suggesting superior cash flow management.

Dilution risk is assessed as low, providing some protection against equity value erosion from share issuance.

The company reported a net loss of 8.6 billion KRW, resulting in a negative net margin of -46.8%.

Operating margin of -43.1% places the company in the bottom quartile of its biotechnology cohort peers.

Credit risk is flagged as high, signaling significant potential issues with debt servicing or financial stability.

Debt-to-equity ratio of 0.67 is in the bottom quartile, indicating higher leverage than most cohort peers.

Free cash flow remained deeply negative at -7.5 billion KRW, highlighting persistent cash burn despite revenue growth.